Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:TLC

Taiwan Liposome (TLC) Stock Price, News & Analysis

Taiwan Liposome logo

About Taiwan Liposome Stock (NASDAQ:TLC)

Advanced Chart

Key Stats

Today's Range
$7.00
$7.09
50-Day Range
$6.76
$7.63
52-Week Range
$4.07
$7.70
Volume
12,421 shs
Average Volume
133,095 shs
Market Capitalization
$294.54 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive TLC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Taiwan Liposome and its competitors with MarketBeat's FREE daily newsletter.

TLC Stock News Headlines

Cold War Discovery Could Unlock $100 Trillion in Wealth
Obscure Metal More Valuable than Gold and Bitcoin… COMBINED? This strange "AI Metal" holds the key to the $100 trillion AI boom. Which is why Jeff Brown recently traveled to a location that has one of the highest concentrations of this metal in the world. And you won't believe what he uncovered.
See More Headlines

TLC Stock Analysis - Frequently Asked Questions

Taiwan Liposome Company, Ltd. (NASDAQ:TLC) announced its quarterly earnings results on Wednesday, October, 28th. The company reported ($0.19) EPS for the quarter, missing analysts' consensus estimates of ($0.13) by $0.06. The company earned $2.28 million during the quarter, compared to analysts' expectations of $0.38 million. Taiwan Liposome had a negative trailing twelve-month return on equity of 120.45% and a negative net margin of 299.27%.

Taiwan Liposome (TLC) raised $29 million in an initial public offering on the week of November 19th 2018. The company issued 5,000,000 shares at $5.80 per share. Cantor acted as the underwriter for the IPO and CLSA, H.C. Wainwright, Janney Montgomery Scott and Laidlaw & Company (UK) Ltd. were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Taiwan Liposome investors own include Avino Silver & Gold Mines (ASM), Trevena (TRVN), Bionano Genomics (BNGO), Pfizer (PFE), Wells Fargo & Company (WFC), Aadi Bioscience (AADI) and BioLineRx (BLRX).

Company Calendar

Last Earnings
10/28/2020
Today
7/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:TLC
Fax
N/A
Employees
2,020
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$35.02 million
Net Margins
-299.27%
Pretax Margin
-306.10%

Debt

Sales & Book Value

Annual Sales
$3.63 million
Price / Cash Flow
N/A
Book Value
$0.83 per share
Price / Book
8.43

Miscellaneous

Free Float
N/A
Market Cap
$294.54 million
Optionable
Not Optionable
Beta
0.99
10 Stocks Set to Soar in Summer 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:TLC) was last updated on 7/6/2025 by MarketBeat.com Staff
From Our Partners